NZ624222B2 - Paste comprising non-steroidal anti-inflammatory drug - Google Patents
Paste comprising non-steroidal anti-inflammatory drug Download PDFInfo
- Publication number
- NZ624222B2 NZ624222B2 NZ624222A NZ62422212A NZ624222B2 NZ 624222 B2 NZ624222 B2 NZ 624222B2 NZ 624222 A NZ624222 A NZ 624222A NZ 62422212 A NZ62422212 A NZ 62422212A NZ 624222 B2 NZ624222 B2 NZ 624222B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- paste
- paste according
- amount
- present
- agent
- Prior art date
Links
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 title abstract description 36
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 23
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960001929 meloxicam Drugs 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 11
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 11
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 11
- 239000000230 xanthan gum Substances 0.000 claims abstract description 11
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 11
- 229940041667 Oral Paste Drugs 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 35
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 206010048592 Musculoskeletal disease Diseases 0.000 claims description 14
- 230000001154 acute Effects 0.000 claims description 14
- 230000001684 chronic Effects 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 10
- 239000000080 wetting agent Substances 0.000 claims description 10
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 230000002335 preservative Effects 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 235000013615 non-nutritive sweetener Nutrition 0.000 claims description 8
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drugs Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000001458 anti-acid Effects 0.000 claims description 2
- 230000000845 anti-microbial Effects 0.000 claims description 2
- 230000000840 anti-viral Effects 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- 206010068760 Ulcers Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002702 piroxicam Drugs 0.000 abstract description 3
- 229920000591 gum Polymers 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 239000004150 EU approved colour Substances 0.000 description 4
- 235000011430 Malus pumila Nutrition 0.000 description 4
- 240000007119 Malus pumila Species 0.000 description 4
- 235000015103 Malus silvestris Nutrition 0.000 description 4
- 229940068968 Polysorbate 80 Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000006194 liquid suspension Substances 0.000 description 4
- 229940006093 opthalmologic coloring agents Diagnostic Drugs 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 3
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960003184 carprofen Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001888 polyacrylic acid Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000001962 taste-modifying agent Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940014259 Gelatin Drugs 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- -1 hydroxyethylpropyl Chemical group 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 150000005599 propionic acid derivatives Chemical class 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 1
- OSNSWKAZFASRNG-BMZZJELJSA-N (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical class O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-BMZZJELJSA-N 0.000 description 1
- IVBOUFAWPCPFTQ-SFYZADRCSA-N (3S)-3-azaniumyl-4-oxo-4-[[(2R)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoate Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C IVBOUFAWPCPFTQ-SFYZADRCSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 229960005164 ACESULFAME Drugs 0.000 description 1
- 229960004998 Acesulfame potassium Drugs 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940023476 Agar Drugs 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 229950008138 Carmellose Drugs 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940111134 Coxibs Drugs 0.000 description 1
- 240000005497 Cyamopsis tetragonoloba Species 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N Dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M Dioctyl sodium sulfosuccinate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229960000878 Docusate Sodium Drugs 0.000 description 1
- 210000002969 Egg Yolk Anatomy 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N Fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 229960004369 Flufenamic Acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N Isomalt Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000035888 Maximum plasma concentration Effects 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 235000016247 Mentha requienii Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 229940001676 Metacam Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N Neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-NRRCNVALSA-N Neohesperidin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3cc(O)c(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 ARGKVCXINMKCAZ-NRRCNVALSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N Neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229950005134 Polycarbophil Drugs 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068984 Polyvinyl Alcohol Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L Potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 240000002799 Prunus avium Species 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 240000003497 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 229950005175 SUDOXICAM Drugs 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229960001462 Sodium Cyclamate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- UEDUENGHJMELGK-VESORUSYSA-N Stevioside Natural products O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 UEDUENGHJMELGK-VESORUSYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229950009638 TEPOXALIN Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 229940100445 WHEAT STARCH Drugs 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drugs Oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic products Propionic acid derivatives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000006682 bigleaf mint Nutrition 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LNMAXKMUGYXKPJ-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 LNMAXKMUGYXKPJ-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000006679 mint Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M potassium;6-methyl-2,2-dioxooxathiazin-4-olate Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035513 volume of distribution Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Provided is an oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug (NSAID); (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle. Preferred NSAIDs include meloxicam and piroxicam. Preferred viscosity modifying agents include hydroxypropyl cellulose and xanthan gum or mixtures thereof. than gum or mixtures thereof.
Description
PASTE COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUG
The present invention generally relates to oral pastes
comprising a non-steroidal anti-inflammatory drug, such as
meloxicam, a method of their production and their use in the
alleviation of inflammation and pain in both acute and
chronic musculoskeletal disorders in animals, especially
horses.
Numerous pharmaceutically acceptable oral dosage forms, such
as liquid suspensions, are known in the art. Such
suspensions are liquid systems having solid particles
dispersed substantially throughout.
EP-A-1,066,029 (Metacam ) describes a suspension for non-
steroidal anti-inflammatory drugs that comprises about 0.1
to about 5% by weight of a highly dispersed silicon dioxide
and about 0.05 to about 2% by weight of a hydrophilic
polymer.
EP-A-1,520,578 further describes another suspension system
for pharmaceuticals that comprises xanthan gum, a swelling
agent, such as pregelatinised starch, a surfactant such as
polyoxyethylene sorbitan monoleate, an amino polycarboxylic
acid or salt thereof such as ethylenediaminetetraacetic acid
(EDTA), and optionally a nucleation inhibitor, such as
polyvinylpyrrolidone. Taste modifying agents, such as
sugars, artificial sweetener, flavouring agents and mixtures
thereof, can also be present and generally comprise 25 to 50
% by weight of the total composition.
WO-A-2006/061351 further describes a suspension comprising
meloxicam suspended in an aqueous glycerol mixture, a
thickening agent, one or more taste modifying agents and a
buffer system for maintaining the pH in a range from 2 to 4,
wherein the suspension is free or essentially free of
silicon dioxide.
A common problem associated with the oral dosage forms, such
as liquid suspensions, is that the suspensions are runny
which result in them being easily split when administered to
animals, especially horses, and that they have a high
sedimentation rate.
Such problems result in an inaccuracy of the dose
administered to the animal and an inefficient method of
administering an active ingredient to an animal. To
compensate for the loss of active ingredient due to
separation and sedimentation the person administering the
dose to the animal would need to administer another partial
dose to ensure that a sufficient amount of active ingredient
is administered. It would, however, be difficult to
calculate the exact amount of active ingredient required and
too much may, therefore, be ultimately administered to the
animal. This is dangerous as several active ingredients,
such as meloxicam, are toxic and, therefore, any over dosing
could, therefore, be potentially fatal.
There is, therefore, a need to provide an oral dosage form
which is efficient, can be accurately administered to an
animal and is, therefore, safe to use.
It has now been surprisingly found that an oral dosage form
in the form of a paste overcomes the problems associated
with the known liquid suspensions as the paste does not
separate in use and sedimentation does not occur and/or a
paste at least provides the public with a useful choice.
Paste formulations are also advantageous in that they are
ready to use and do not require to be shaken/mixed before
use, in contrast to known liquid suspensions.
Hence according to the present invention there is provided
an oral paste comprising:
(i) meloxicam;
(ii) at least one viscosity modifying agent selected
from the group consisting of hydroxypropylcellulose, xanthan
gum or mixtures thereof; and
(iii) a liquid vehicle.
Also described is an oral paste comprising:
(i) at least one non-steroidal anti-inflammatory drug;
(ii) at least one viscosity modifying agent; and
(iii) a liquid vehicle.
The present invention further provides a process for the
manufacture of the oral paste as defined in the invention
comprising the following steps:
a) adding at least one viscosity modifying agent to a liquid
vehicle and mixing until a homogeneous gel is made; and
b) adding the meloxicam to the homogeneous gel of step a)
whilst stirring to obtain a paste.
Also described is a process where another non-steroidal
anti-inflammatory drug is used in step b).
In another aspect, the invention provides a paste as defined
in the invention for use in a method of treatment for the
alleviation of pain and inflammation in both acute and
chronic musculoskeletal disorders in animals.
In another aspect, the invention provides the paste as
defined in the invention for use in alleviating pain and
inflammation in both acute and chronic musculoskeletal
disorders in animals.
In another aspect, the invention relates to the use of the
paste as defined in the invention for the manufacture of a
medicament for the alleviation of pain and inflammation in
both acute and chronic musculoskeletal disorders in animals.
In another aspect, the invention provides a method of
treating or alleviating pain and inflammation in both acute
and chronic musculoskeletal disorders in an animal patient
comprising administering to a patient in need thereof an
effective amount of a paste according to the invention,
provided the patient is not a human.
Certain statements that appear below are broader than what
appears in the statements of the invention above. These
statements are provided in the interests of providing the
reader with a better understanding of the invention and its
practice. The reader is directed to the accompanying claim
set which defines the scope of the invention.
Also described is an oral paste for use in a method of
treatment of the animal body by therapy.
Also described is an oral paste for use in alleviating pain
and inflammation in both acute and chronic musculoskeletal
disorders in animals.
Also described is an oral paste for use in a method of
treatment for the alleviation of pain and inflammation in
both acute and chronic musculoskeletal disorders in animals.
Also described is the use of an oral paste for the
manufacture of a medicament for the alleviation of pain and
inflammation in both acute and chronic musculoskeletal
disorders in animals.
Also described is a method of treating or alleviating pain
and inflammation in both acute and chronic musculoskeletal
disorders in an animal patient comprising administering to a
patient in need thereof an effective amount of the oral
paste.
The present invention will now be further described. In the
following passages different aspects of the invention are
defined in more detail. Each aspect so defined may be
combined with any other aspect or aspects unless clearly
indicated to the contrary. In particular, any feature
indicated as being preferred or advantageous may be combined
with any other feature or features indicated as being
preferred or advantageous.
The oral pharmaceutical composition of the present invention
is in the form of a paste.
A paste is a two-component semi-solid in which a drug, in
this instance a non-steroidal anti-inflammatory drug, is
dispersed as a powder in a liquid vehicle. The paste
preferably has a viscosity of from about 7000 to about 15000
cps as measured by a Brookfield viscometer, spindle size 18
at a speed of 1 RPM and a temperature of 25 °C.
The liquid vehicle can be an aqueous or fatty base, for
example. The liquid vehicle containing the non-steroidal
anti-inflammatory drug can be selected from the group
consisting of water, a polyhydroxy liquid such as glycerin,
propylene glycol, or polyethylene glycol, a vegetable oil or
a mineral oil, including mixtures of two or more thereof. In
a preferred embodiment the liquid vehicle is water. The
particle size of the active ingredient in the paste can be
as large as 100 µm.
One or more non-steroidal anti-inflammatory drugs can be
selected from the group comprising of salicylates such as
aspirin, methyl salicylate, Diflunisal and amoxiprin;
acetaminophen; arylalkanoic acids such as diclofenac,
indomethacin and sulindac; propionic acid derivatives
(profens) such as ibuprofen, carprofen, naproxen and
ketoprofen; N-Arylanthranlic acids (fenamic acid
derivatives) such as mefanamic acid, meclofenamic acid and
flufenamic acid; oxicams such as piroxicam, sudoxicam,
isoxicam and meloxicam; coxibs such as celecoxib, rofecoxib,
valdecoxib, parecoxib and etoricoxib; sulphonanilides such
as nimesulide; and non-steroidal anti-inflammatory drugs
that have both cyclo-oxygenase (II) and lipooxygenase
inhibition properties such as tepoxalin and mixtures of two
or more thereof.
The non-steroidal anti-inflammatory drug is preferably an
oxicam, a propionic acid derivative or mixtures thereof.
More preferably the non-steroidal anti-inflammatory drug is
meloxicam, piroxicam, carprofen, ibuprofen, ketoprofen or
mixtures thereof, more preferably meloxicam or carprofen and
most preferably meloxicam.
The amount of non-steroidal anti-inflammatory drug present
in the paste should be sufficient to provide a therapeutic
amount of the active and a convenient dosage unit.
Accordingly, the at least one non-steroidal anti-
inflammatory drug can be present in an amount of from about
1 to about 10% w/v of the paste, preferably about 3 to about
8% w/v of the paste, even more preferably about 4% to about
6% w/v of the paste, and most preferably in an amount of
about 5% w/v of the paste.
In a preferred embodiment the non-steroidal anti-
inflammatory drug is present in both micronised and
unmicronised form.
The non-steroidal anti-inflammatory drug in its micronised
form will have a D (diameter of 50% of particles) of less
than about 10 microns, for example from about 1 to about 10
microns, preferably less than about 5 microns.
The non-steroidal anti-inflammatory drug in its unmicronised
form will have a D (diameter of 50% of particles) of
greater than about 10 microns, for example from about 10 to
about 200 microns, preferably less than abou 100 microns.
The particle size is measured by laser diffraction. The
particles of the non-steroidal anti-inflammatory drug having
a D (diameter of 50% of particles) of less than 10 microns
can be obtained for example by micronisation or by milling.
Preferably the particles are obtained by micronisation.
In a preferred embodiment at least about 60% of the total
amount of the non-steroidal anti-inflammatory drug, more
preferably between about 70 to about 80% of the particles,
and most preferably at least about 74% is micronised. In one
embodiment all of the non-steroidal anti-inflammatory drug
can be present in the micronised form.
In a preferred embodiment about 40% of the total amount of
the non-steroidal anti-inflammatory drug, more preferably
between about 25 to about 35% of the particles, and most
preferably at least about 26% is unmicronised. In one
embodiment all of the non-steroidal anti-inflammatory drug
can be present in unmicronised form.
In a preferred embodiment the micronised form of the non-
steroidal anti-inflammatory drug is present in an amount of
at about 74% of the total amount of non-steroidal anti-
inflammatory drug present and the non-steroidal anti-
inflammatory drug in its unmicronised form is present in an
amount of about 26% of the total amount of non-steroidal
anti-inflammatory drug present.
The non-steroidal anti-inflammatory drug can also be used in
combination with other drugs such as but not limited to
antimicrobials, antibiotics, antivirals, anti-ulcer/anti-
acid agents and anti-cancer agents or a combination of two
or more thereof.
The non-steroidal anti-inflammatory drug(s) are present in a
"unit dose volume" of the paste in a therapeutically
effective amount, which is in an amount that produces the
desired therapeutic response upon oral administration. In
determining such amounts, the particular non-steroidal anti-
inflammatory drug(s) being administered, the bioavailability
characteristics of the non-steroidal anti-inflammatory drug
, the dose regime, the age and weight of the recipient, and
other factors must be considered, as known in the art. As
used herein a "unit dose volume" of the paste is a
convenient volume for dosing the product to a recipient. The
dosing directions instruct the recipient to take amounts
that are multiples of the unit dose depending on for example
the age or weight of the recipient. Typically the unit dose
volume of the paste will contain an amount of non-steroidal
anti-inflammatory drug that is therapeutically effective for
the smallest patient. An effective amount may be achieved by
multiple dosing.
The paste is administered in such an amount that a single
daily dosage comprises from about 0.05 mg to about 1.0 mg of
non-steroidal anti-inflammatory drug/kg body weight. In a
preferred embodiment a typical once daily dosage ranges from
about 0.5 to about 0.7 mg, and most preferably in an amount
of about 0.6 mg non-steroidal anti-inflammatory drug/kg body
weight.
The paste is to be administered directly into the mouth of
the animal. Dosing of the paste can be done using an
appropriate metering system such as, for example a
calibrated syringe, or a pre-filled dispenser that can
deliver calibrated amounts of the paste.
In a preferred embodiment the paste is administered directly
into the mouth of the animal, once daily for up to 14 days.
The degree of cohesiveness, plasticity, and syringeability
of pastes is attributed to the viscosity modifying agent. At
least one viscosity modifying agent is present in the paste.
Examples of viscosity modifying agents include
hydroxypropylcellulose, methylcellulose,
hydroxyethylcellulose, hydroxypropylmethyl cellulose,
hydroxyethylpropyl celluose, polyethylene glycol, propylene
glycol, starches, such as maize or corn starch, potato
starch, rice starch, tapioca starch and wheat starch,
hydroxypropyl starch, carboxyvinyl polymers, carbomers such
as Carbopol, carboxymethyl cellulose and salts thereof,
microcrystalline cellulose, agar, polyvinyl alcohol, alginic
acid, potassium alginate, polyvinyl pyrrolidone, carmellose
sodium, maltodextrin, dextrin, gelatin, pectin, poloxamer,
polycarbophil, pregelatinised starch, polysaccharide gums
such as guar, acacia, gellan, carrageenan, xanthan and
tragacanth gums and mixtures of two or more thereof.
In a preferred embodiment the viscosity modifying agent is
selected from the group consisting of
hydroxypropylcellulose, xanthan gum and mixtures thereof.
More preferably xanthan gum and hydroxypropylcellulose are
present as viscosity modifying agents.
Examples of suitable xanthan gums that can be used include
TM TM TM TM TM
Rhodigel 80 , Rhodigel 23 , Keltrol , Keltrol F, Keltrol
TM TM TM TM
T, Keltrol TF, Keltrol 1000 and Merezan . Rhodigel 23 is
preferred.
The viscosity modifying agents can be present in an amount
of from about 0.5 to about 25 % w/v of the paste, preferably
in an amount of from about 1 to about 20 % w/v of the paste,
more preferably in an amount of from about 2 to about 15 %
w/v of the paste, even more preferably in an amount of from
3 to 10% w/v of the paste and most preferably present in an
amount of about 4 % w/v of the paste.
In a preferred embodiment when xanthan gum and
hydroxypropylcellulose are present as viscosity modifying
agents the xanthan gum is present in an amount of from about
0.1 to about 5% w/v of the paste, preferably in an amount of
from about 0.5 to about 2% w/v of the paste, and most
preferably in an amount of about 0.8% w/v of the paste and
the hydroxypropyl cellulose is present in an amount of from
about 1 to about 8 % w/v of the paste, preferably in an
amount of from about 2 to about 5% w/v of the paste, and
most preferably in an amount of about 3% w/v of the paste.
The paste may also contain a wetting agent and/or a
stabiliser.
Wetting agents may be surfactants, hydrophilic colloids or
solvents.
Surfactants can be ionic, non-ionic, cationic and
amphiphilic surfactants. Examples of suitable ionic and non-
ionic surfactants include sodium lauryl sulphate, sulphate,
docusate sodium, polysorbate 80, poloxamers and povidones.
An example of a suitable cationic surfactant is
cetyltrimethyl ammoinum bromide. Examples of suitable
amphiphilic surfactants include tweens, pluronics, cremophor
and solutol.
Examples of suitable hydrophilic colloids include acacia,
tragacanth, alginates, guar gum, pectin, gelatin, wool fat,
egg yolk, bentonite, Veegum and methylcellulose.
Examples of suitable solvents include alcohol, glycerol,
polyethylene glycol and polypropylene glycol.
In a preferred embodiment the wetting agent is selected from
the group consisting of glycerol, polysorbate 80,
polyethylene glycol and mixtures of two or more thereof.
Most preferably the wetting agent is glycerol.
Wetting agents can be present in an amount of from about 0
to about 50% w/v of the paste, preferably in an amount of
from about 5 to about 30% w/v of the paste, more preferably
in an amount of from about 10 to about 20% w/v of the paste
and most preferably in an amount of about 15% w/v of the
paste.
Examples of stabilisers which may be present include natural
gums, cellulose derivatives, and the surfactants and
solvents as detailed above as suitable wetting agents.
Stabilisers can be present in an amount of from about 0 to
about 50% w/v of the paste, preferably in an amount of from
about 5 to about 30% w/v of the paste and more preferably in
an amount of from about 10 to about 20% w/v of the paste.
In a preferred embodiment the stabiliser is selected from
the group consisting of glycerol, polysorbate 80,
polyethylene glycol and mixtures of two or more thereof.
Most preferably the stabiliser is glycerol.
In a preferred embodiment the paste includes glycerol,
polysorbate 80 or polyethylene glycol as a wetting agent and
a stabiliser. When the component acts as both the wetting
agent and stabiliser it can be present in an amount of from
about 0.5 to about 50% w/v of the paste, preferably from
about 10 to about 30% w/v of the paste, and most preferably
in an amount of about 15% w/v of the paste.
The pastes may also contain one or more of the following
additives: preservatives, taste modifying agents such as
flavouring agents, bulk sweeteners, intense sweeteners,
colourings and humectants.
In order to protect the oral pastes of the present invention
from microbial contamination during use, a preservative can
be added. This preservative is preferably selected from the
group consisting of benzoic acid and the sodium or potassium
salts thereof, scorbic acid and the sodium or potassium
salts thereof, benzyl alcohol, methyl alcohol, phenolic
compounds such as phenol, quaternary compounds such as
benzalkonium chloride, methyl parahydroxybenzoate, ethyl
para-hydroxybenzoate, propyl parahydroxybenzoate, butyl
parahydroxybenzoate, parabens such as methyl, ethyl, propyl
and butyl and mixtures of two or more thereof. In a
preferred embodiment the preservative is benzyl alcohol.
The preservative can be present in an amount of from about
0.02 to about 5% w/v of the paste, preferably about 0.1 to
about 3% w/v of the paste and most preferably in an amount
of about 1% w/v of the paste.
Examples of bulk sweeteners are sorbitol, mannitol,
fructose, sucrose, maltose, isomalt, glucose, hydrogenated
glucose syrup and xylitol, and mixtures of two or more
thereof. In a preferred embodiment the bulk sweetener is
sorbitol.
The bulk sweetener can be present in an amount of from about
1 to about 10% w/v of the paste, preferably about 3 to about
6% w/v of the paste, more preferably about 5 to about 6% w/v
of the paste and most preferably in an amount of about 5.6%
w/v of the paste.
Examples of intense sweeteners are saccharin, aspartame,
acesulfame, cyclamate, alitame, taumatin, a dihydrochalcone
sweetener, monellin, neohesperidin, neotame, stevioside and
sucralose, the pharmaceutically acceptable salts thereof
such as sodium or calcium saccharin, acesulfame potassium or
sodium cyclamate, and mixtures of two or more thereof. In a
preferred embodiment the intense sweetener is sodium
saccharin.
The intense sweetener can be present in an amount of from
about 0.01 to about 1% w/v of the paste, preferably about
0.03 to about 0.08% w/v of the paste, more preferably about
0.05 to about 0.07% w/v of the paste, and most preferably in
an amount of about 0.07% w/v of the paste.
Examples of flavouring agents are apple, cherry, raspberry,
blackcurrant, strawberry flavour, honey, chocolate flavour
and mint cool flavour. In a preferred embodiment the
flavouring agent is apple.
Flavouring agents can be present in an amount of from 0.01
to about 3% w/v of the paste, preferably about 0.1 to about
1% w/v of the paste, and most preferably about 0.3% w/v of
the paste.
Colouring agents may also be incorporated in the paste to
provide an appealing colour to the paste. The colouring
agents should be selected to avoid chemical
incompatibilities with the other ingredients in the paste.
Examples of suitable colouring agents include FD&C Red #40,
FD&C Blue #1 and FD&C Red #33.
Colouring agents can be present in an amount of from about 0
to about 0.1% w/v of the paste, preferably about 0 to about
0.0001% w/v of the paste, and most preferably about 0 to
about 0.001% w/v of the paste.
Humectants are used to prevent the paste that may collect at
the nozzle of a dispenser from forming a hard crust.
Examples of humectants include glycerin and propylene
glycol.
Humectants can be present in an amount of from about 0 to
about 20% w/v of the paste, preferably about 0 to about 5%
w/v of the paste, and most preferably about 0 to about 2%
w/v of the paste.
In a preferred embodiment the paste is prepared by a) adding
at least one viscosity modifying agent to a vehicle and
mixing until a homogeneous gel is made; and
b) adding the non-steroidal anti-inflammatory drug to the
homogeneous gel of step a) whilst stirring to obtain a
paste.
The pastes can be used in the treatment of animals against
disease. In particular the pastes can be used to alleviate
inflammation and pain in both acute and chronic
musculoskeletal disorders in animals, and in particular in
horses.
The invention will now be described with respect to the
following examples. The examples are not intended to be
limiting of the scope of the present invention but read in
conjunction with the detailed and general description above,
provide further understanding of the present invention and
an outline of the preferred processes for preparing the
pastes of the invention.
Example 1
The composition of the paste of the current invention is
provided in Table 1.
Ingredient % w/v
Meloxicam (micronised) 3.7
Meloxicam (unmicronised) 1.3
Hydroxypropylcellulose 3.0
Glycerol 15.0
Xanthan Gum 0.8
Apple flavour 0.3
Sodium Saccharin 0.07
Sorbitol 5.6
Benzyl alcohol 1.0
Purified water to 100 g
The paste was prepared by adding the xanthan gum and
hydroxypropyl cellulose into purified water and mixing
together until a homogeneous gel was formed. Glycerol was
added while stirring. Meloxicam was then added while
stirring. Apple flavour, sodium saccharin, sorbitol and
benzyl alcohol were then added while stirring.
The paste was administered directly into the mouth of the
animal using a syringe. The unit dose volume was 0.6 mg
meloxicam/kg body weight, once daily for up to 14 days.
The oral bioavailability was approximately 98%. Maximal
plasma concentrations were obtained after approximately 4
hours. The accumulated factor of 1.08 suggests that
meloxicam does not accumulate when administered daily.
Approximately 98% of meloxicam is bound to plasma proteins.
The volume of distribution is 0.12 l/kg.
The term ‘comprising’ as used in this specification and
claims means ‘consisting at least in part of’. When
interpreting statements in this specification and claims
which includes the ‘comprising’, other features besides the
features prefaced by this term in each statement can also be
present. Related terms such as ‘comprise’ and ‘comprised’
are to be interpreted in similar manner.
In this specification where reference has been made to
patent specifications, other external documents, or other
sources of information, this is generally for the purpose of
providing a context for discussing the features of the
invention. Unless specifically stated otherwise, reference
to such external documents is not to be construed as an
admission that such documents, or such sources of
information, in any jurisdiction, are prior art, or form
part of the common general knowledge in the art.
WE
Claims (37)
1. An oral paste comprising: (i) meloxicam; 5 (ii) at least one viscosity modifying agent selected from the group consisting of hydroxypropylcellulose, xanthan gum or mixtures thereof; and (iii) a liquid vehicle. 10
2. A paste according to claim 1 wherein the meloxicam is present in an amount of from about 3 to about 8% w/v of the paste.
3. A paste according to claim 2 wherein the meloxicam is 15 present in an amount of about 5% w/v of the paste.
4. A paste according to any one of claims 1 to 3 wherein at least about 74% of the meloxicam particles have a D (diameter of 50% of particles) of less than about 10 20 microns.
5. A paste according to any one of the preceding claims wherein the viscosity modifying agent is hydroxypropyl cellulose and xanthan gum.
6. A paste according to any one of the preceding claims wherein the at least one viscosity modifying agent is present in an amount of from about 2 to about 15% w/v of the paste.
7. A paste according to claim 6 wherein the at least one viscosity modifying agent is present in an amount of about 4% w/v of the paste. 5
8. A paste according to any one of the preceding claims which further comprises a wetting agent and/or a stabiliser.
9. A paste according to claim 8 wherein the wetting agent and/or the stabiliser is glycerol.
10. A paste according to claim 9 wherein the glycerol is present in an amount of about 15% w/v of the paste.
11. A paste according to any one of the preceding claims 15 which further comprises a flavouring agent.
12. A paste according to claim 11 wherein the flavouring agent is an apple flavour. 20
13. A paste according to claim 11 or 12 wherein the flavouring agent is present in an amount of from about 0.1 to about 1 % w/v of the paste.
14. A paste according to claim 13 wherein the flavouring 25 agent is present in an amount of about 0.3% w/v of the paste.
15. A paste according to any one of the preceding claims which further comprises a bulk sweetener.
16. A paste according to claim 15 wherein the bulk sweetener is sorbitol.
17. A paste according to claim 15 or 16 wherein the bulk sweetener is present in an amount of from about 3% w/v to about 6% w/v of the paste.
18. A paste according to claim 17 wherein the bulk sweetener is present in an amount of about 5.6 % w/v of the paste. 10
19. A paste according to any one of the preceding claims which further comprises an intense sweetener.
20. A paste according to claim 19 wherein the intense sweetener is sodium saccharin.
21. A paste according to claim 19 or 20 wherein the intense sweetener is present in an amount of from about 0.03% w/v to about 0.08% w/v of the paste. 20
22. A paste according to claim 21 wherein the intense sweetener is present in an amount of about 0.07 % w/v of the paste.
23. A paste according to any one of the preceding claims 25 which further comprises a preservative.
24. A paste according to claim 23 wherein the preservative is benzyl alcohol. 30
25. A paste according to claim 23 or 24 wherein the preservative is present in an amount of from about 0.1 to about 3 % w/v of the paste.
26. A paste according to claim 25 wherein the preservative is present in an amount of about 1 % w/v of the paste. 5
27. A paste according to any one of the preceding claims further comprising at least one other drug.
28. A paste according to claim 27 wherein the at least one other drug is an antimicrobial, antibiotic, antiviral, anti- 10 ulcer/anti-acid or anti-cancer agent or a combination of two or more thereof.
29. A paste according to any one of the preceding claims wherein the liquid vehicle is water.
30. A process for the manufacture of the paste as defined in any one of claims 1 to 29, comprising the following steps: a) adding at least one viscosity modifying agent to the 20 liquid vehicle and mixing until a homogeneous gel is made; b) adding the meloxicam to the homogeneous gel of step a) whilst stirring to obtain a paste. 25
31. A paste as defined in any one of claims 1 to 29 for use in a method of treatment for the alleviation of pain and inflammation in both acute and chronic musculoskeletal disorders in animals. 30
32. The paste as defined in any one of claims 1 to 29 for use in alleviating pain and inflammation in both acute and chronic musculoskeletal disorders in animals.
33. Use of the paste as defined in any one of claims 1 to 29 for the manufacture of a medicament for the alleviation of pain and inflammation in both acute and chronic 5 musculoskeletal disorders in animals.
34. A method of treating or alleviating pain and inflammation in both acute and chronic musculoskeletal disorders in an animal patient comprising administering to a 10 patient in need thereof an effective amount of a paste according to any one of claims 1 to 29, provided the patient is not a human.
35. A paste according to any one of claims 1 to 29, 31 and 15 32 substantially as herein described with reference to any example thereof.
36. A use according to claim 33, substantially as herein described with reference to any example thereof.
37. A method according to claim 34, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1117858.9A GB201117858D0 (en) | 2011-10-17 | 2011-10-17 | Paste |
GB1117858.9 | 2011-10-17 | ||
PCT/GB2012/000790 WO2013057461A1 (en) | 2011-10-17 | 2012-10-16 | Paste comprising non-steroidal anti-inflammatory |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624222A NZ624222A (en) | 2016-01-29 |
NZ624222B2 true NZ624222B2 (en) | 2016-05-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1824493B1 (en) | Oral suspension comprising meloxicam | |
CA2567075C (en) | Pharmaceutical suspension composition | |
CA2649895C (en) | Stable hydroalcoholic oral spray formulations and methods | |
AU2007253083B2 (en) | Stable aqueous suspension having palatable taste | |
JP2013241422A (en) | Stable aqueous suspension preparation | |
TWI327913B (en) | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid | |
AU2012324605B2 (en) | Paste comprising non-steroidal anti-inflammatory | |
NZ624222B2 (en) | Paste comprising non-steroidal anti-inflammatory drug | |
AU2013318356A1 (en) | Low melting propionic acid derivative particles for use in oral dosage forms | |
EP2594258B1 (en) | Oral gel comprising praziquantel | |
JP2023508085A (en) | Liquid composition comprising ibuprofen and phenylephrine | |
AU2018202909A1 (en) | Sustained release oral dosage forms comprising low melting propionic acid derivative particles | |
US20140256810A1 (en) | Low melting propionic acid derivative particles for use in oral dosage forms |